Effects of interrupted insulin treatment on fetal outcome of pregnant diabetic rats.
Streptozocin-induced diabetic female rats became normoglycemic after subcutaneous insertion of insulin-releasing osmotic minipumps. These female rats were mated with normal males from the same Sprague-Dawley substrain. In this substrain, the offspring of diabetic rats show a markedly increased congenital malformation rate compared with fetuses of nondiabetic rats. The pregnant diabetic rats were subjected to removal and insertion of pumps at defined gestational days that marked the beginning or end of a 2- or 4-day period of insulin withdrawal. Evaluation of the offspring on day 20 of pregnancy included fetal/placental weights, estimated number of implants, resorptions, and morphological assessment of congenital malformations. Resorptions occurred in all interruption groups, but malformations were found only in animals with insulin withdrawal on gestational days 4-8, 6-8, 6-10, 8-10, and 8-12. The highest resorption (42%) and malformation (17%) rates were found in the rats subjected to insulin withdrawal during gestational days 6-10. Because manifestly diabetic rats with no insulin treatment showed similar resorption (39%) and malformation (17%) rates, this study suggests that a teratogenic period in diabetic rat pregnancy occurs during gestational days 6-10, a period corresponding to postconceptional wk 2-4 in human pregnancy. Interruption of insulin treatment induced similar maternal weight loss and similar maternal serum concentrations of D-glucose, cholesterol, urea, and creatinine in rats with and without malformed offspring.(ABSTRACT TRUNCATED AT 250 WORDS)
Eriksson
R S
RS
Department of Medical Cell Biology, University of Uppsala, Sweden.
Thunberg
L
L
Eriksson
U J
UJ
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D000013:Congenital Abnormalities / Q000209:etiology*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D005260:Female; D005333:Fetus / Q000187:drug effects / Q000502:physiology; D005865:Gestational Age; D006885:Hydroxybutyrates; D007328:Insulin / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011254:Pregnancy in Diabetics / Q000188:drug therapy / Q000503:physiopathology*; D051381:Rats; D011919:Rats, Inbred Strains
D001786:Blood Glucose; D006885:Hydroxybutyrates; D007328:Insulin; C031570:2-hydroxybutyric acid